Vesugen
Vascular-endothelium tripeptide taken in short courses to support endothelial function and vessel-wall health, and the bioregulator most often paired with cardiac and metabolic stacks.
Also known as Lys-Glu-Asp, KED, KED tripeptide, vascular Cytogen, Vezugen, Vesugen
In vitro only — Cell or tissue studies. A mechanism, not yet an effect in a living body.
The evidence is endothelial and smooth-muscle cell-culture work plus molecular docking from Khavinson's institute showing changes in endothelial gene expression. There are no animal outcome studies of note and no human data. Everything cardiovascular claimed for this peptide is an extrapolation from a dish.
How it works
Vesugen is Lys-Glu-Asp. In endothelial and vascular smooth muscle cell culture, Khavinson's group reports that KED increases expression of endothelial markers such as CD31 and VEGF, modulates eNOS-related signalling and reduces markers of endothelial senescence. The proposed mechanism is the same as the rest of the class: a small charged peptide crossing into the nucleus, binding DNA in the major groove and de-repressing tissue-specific genes. Some of the more interesting recent work is molecular docking rather than wet-lab confirmation. There is no human vascular endpoint data of any kind - no flow-mediated dilation study, no blood pressure trial, nothing.
Targets: Vascular endothelium, CD31/PECAM-1 expression, VEGF signalling, Endothelial nitric oxide synthase
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| Research-market injectable courseAny time of day. | 1 mg – 2 mg | once daily for 10 to 20 days | subcutaneous |
| Oral capsule courseBefore food. | 1 mg – 2 mg | once daily for 20 to 30 days | oral |
- · 20 mg vial reconstituted to 10 mg/mL gives ten to twenty daily doses per vial, which is exactly one course.
- · The capsule route is the mainstream one in Russia; intact absorption remains unproven.
Cycling
Ten to twenty days injectable, or a month of capsules, then off for three to six months. Two to three courses a year is the standard framing.
Pharmacology
- Half-life
- Not measured; a free tripeptide clears from plasma within minutes.
- Onset
- Nothing acute. Claims are framed over a full course and over repeated courses.
- Routes
- subcutaneous, oral
- Molecule
- Synthetic tripeptide
- Sequence length
- 3 amino acids
- Molecular weight
- 390.4 Da
Handling
- Diluent
- Bacteriostatic water
- Typical mix
- 2 or 3 mL
- Vial sizes
- 20 mg
- Lyophilised
- Room temperature short term; fridge or freezer long term.
- Reconstituted
- Refrigerated, use within about 30 days.
- Light sensitive
- Yes — keep it out of the light
Mixing
20 mg in 2 mL gives 10 mg/mL; 1 mg is 10 units on a U-100 syringe.
Side effects
- commonInjection-site irritation— Transient.
- commonNo consistent systemic side effects reported— Exposure data is thin enough that this should not be read as proof of safety.
Do not use if
- Active malignancy - the reported upregulation of VEGF and angiogenic markers is unhelpful here.
- Pregnancy and breastfeeding - no data.
- Proliferative retinopathy - the same angiogenic concern applies.
Combining it
- redundantventfort — Ventfort is the vascular Cytomax extract; Vesugen is its synthetic counterpart. Pick one.
- synergycardiogen — Vessel plus myocardium is the standard Russian cardiovascular pairing.
- cautionbpc-157 — Both are proposed to push angiogenesis; if you have any reason to avoid new vessel growth, stacking them compounds that concern.
What to monitor
- · Blood pressure logged before, during and after a course is the cheapest objective measure available.
- · A lipid panel and hs-CRP if you are using this as part of a cardiovascular protocol.
Legal status
Not approved for human use in the US, UK or EU; sold as a research chemical or as a supplement capsule in Russia and Eastern Europe.
References
- Khavinson et al., KED tripeptide effects on endothelial cell gene expression (Bulletin of Experimental Biology and Medicine) (preclinical)
- Ashapkin, Linkova, Khavinson & Vanyushin, epigenetic mechanisms of peptidergic regulation of gene expression during aging (Biochemistry Moscow) (review)
Mechanism in depth
The interesting thing about KED is that its best-characterised effects are not the ones on the label. Kozlov's group exposed normal, atherosclerotic and restenotic endothelium to the peptide in vitro and reported three specific changes: endothelin-1 expression, which is elevated in atherosclerosis and restenosis, was normalised downward; connexin expression, which governs gap-junction communication between endothelial cells, was restored; and sirtuin-1 expression rose. That last one is the most substantive claim in the file, because SIRT1 is a genuine longevity-associated deacetylase with a role in DNA repair and endothelial nitric oxide synthase activation, and it gives the vascular claim a mechanism that does not depend purely on the chromatin hand-waving. Endothelin-1 downregulation is also a coherent vasoprotective story: ET-1 is the most potent endogenous vasoconstrictor known, and it is elevated in endothelial dysfunction. If KED genuinely lowered ET-1 in a person, that would be measurable and meaningful. The unlabelled finding is neurological: a 2021 paper from Khavinson's group frames KED as a regulator of neurogenesis in Alzheimer's disease models, which sits oddly beside its marketing as a vascular peptide and is a reminder that the tissue assignments in this class are conventions rather than pharmacological facts. What does not exist, anywhere, is a human vascular endpoint. No flow-mediated dilation study, no blood pressure trial, no carotid intima-media thickness data, no ET-1 measurement in a dosed human being.
What usually goes wrong
Substitution is the real harm. Someone with hypertension or a high ApoB runs Vesugen courses instead of treating either, feels fine because endothelial dysfunction is asymptomatic, and loses years of risk reduction. Nothing about this compound has been shown to change a cardiovascular outcome in a human. The second issue is the angiogenesis question: the reported upregulation of endothelial and VEGF-associated markers is sold as a benefit, and in a person with an occult tumour or proliferative retinopathy the same biology is not a benefit. Third, the tissue-specificity claim does not survive contact with the literature - the same peptide has published effects on cortical neurons and Alzheimer's-model neurogenesis, which means whatever it does is not confined to blood vessels.
Bloodwork worth running
| Marker | When | Why it matters |
|---|---|---|
| hs-CRP | Baseline and six weeks after a course. Never test hs-CRP within two weeks of an infection or hard training session - it will be uninterpretable. | The claimed action is endothelial and anti-inflammatory, and hs-CRP is the cheapest routinely available marker that moves with vascular inflammation. It is also the one a cardiologist will actually engage with.Act if: No published human data supports any expected change. If your hs-CRP is above 3 mg/L persistently, that is a cardiovascular risk signal that needs proper management, not a peptide course. |
| Lipid panel with ApoB and Lp(a) | Baseline. Lp(a) once, ever. ApoB and the standard panel at your normal interval. | If you are running a vascular peptide, you should know your actual atherosclerotic risk drivers. ApoB is the particle count that matters and Lp(a) is the once-in-a-lifetime test most people never do.Act if: ApoB above roughly 100 mg/dL in someone with cardiovascular risk, or Lp(a) above 50 mg/dL, is a reason to be on evidence-based therapy. A tripeptide with in vitro data is not a substitute for that and never will be. |
| Home blood pressure log, averaged over seven days | Seven days before the course and seven days starting two weeks after it ends. | Not bloodwork, but it is the cheapest and most honest objective measure available for a vasoprotective claim, and the ET-1 mechanism predicts a direction. Single clinic readings are noise; a seven-day morning-and-evening average is a real number.Act if: A reproducible fall of more than 5 mmHg systolic would be the first genuinely interesting result anyone has produced with this compound. Do not stop antihypertensives on the basis of one good week. |
Pharmacokinetics
- Metabolism
- Aminopeptidase cleavage to lysine, glutamate and aspartate.
- Elimination
- Renal filtration of fragments.
Receptor targets
- Endothelin-1 expression in endothelial cells — No binding data; this is an expression-level effect, not a receptor interaction
Normalisation of ET-1 expression that had been elevated by atherosclerosis or restenosis in vitro. ET-1 is the most potent endogenous vasoconstrictor, so this is the most clinically translatable claim the peptide has.
- Sirtuin-1 (SIRT1)
Increased expression, framed as the geroprotective arm of the effect. SIRT1 is involved in DNA repair and eNOS activation, which is a real mechanistic bridge to endothelial function.
- Connexins / endothelial gap junctions
Restored expression, interpreted as recovery of intercellular communication between endothelial cells.
- Neurogenesis-associated gene expression
Reported regulation of neurogenesis markers in Alzheimer's disease models - an off-label finding that undercuts the tissue-specificity claim rather than supporting it.
- No identified receptor — None published
No receptor exists for this peptide.
What to expect, and when
Nothing acute. There is no perceptible effect from this compound at any point, which is exactly what you would expect from something whose claimed action is endothelial gene expression. Days one to twenty: injection-site irritation and nothing else. Two to six weeks after a course: the only window where a blood pressure average or hs-CRP retest carries any information, and the honest expectation is no change. Anything you feel on this peptide is coming from somewhere else in your stack or from expectation.
Stacking and comparisons
Vesugen plus Cardiogen is the standard Russian cardiovascular pairing - vessel plus myocardium - and it is convention rather than a tested combination. Vesugen plus Ventfort is duplication; Ventfort is the extract, Vesugen the synthetic, and running both pays twice for one claim. The combination worth thinking harder about is with BPC-157: both are proposed to promote angiogenesis, and while neither has strong human data, stacking two pro-angiogenic claims in anyone with a history of malignancy, proliferative retinopathy or an untreated retinal condition compounds a theoretical risk into a less theoretical one. The honest comparison stack for vascular health is not peptide-based: a statin or ezetimibe if ApoB is high, blood pressure control, and stopping smoking each have outcome trials measured in tens of thousands of people.
Against Ventfort: Vesugen is the defined molecule with a published in vitro dataset; Ventfort is an undefined bovine extract in a capsule with none. If you are going to run this claim, run the synthetic. Against Cardiogen: heart versus vessel, both in vitro only, both convention. Against actual cardiovascular therapy: statins, ezetimibe, PCSK9 inhibitors and antihypertensives have outcome data in hundreds of thousands of person-years. Vesugen has one in vitro endothelial paper. Do not confuse the two categories. Against BPC-157 for vascular claims: BPC-157 at least has consistent rodent angiogenesis and healing data; Vesugen's file is thinner and confined to cell culture.
Rough cost
$35–$110/month. One 20 mg vial is one full ten- to twenty-day course. Indicative research-chemical pricing, not verified against vendor listings in this session.
Genuinely uncertain
- No pharmacokinetic data of any kind, by any route, in any species.
- No human vascular endpoint has ever been measured - not flow-mediated dilation, not blood pressure, not intima-media thickness, not endothelin-1.
- All endothelial results are in vitro. Nothing establishes that an injected dose reaches endothelium at a comparable concentration.
- The eNOS and VEGF claims commonly made in marketing are broader than what I could verify; the paper I confirmed reports endothelin-1, connexins and sirtuin-1.
- The tissue-specificity claim is contradicted by the same group's own work on KED in cortical neurons and Alzheimer's models.
- Oral absorption of the intact tripeptide has never been demonstrated.
- Cost figures are indicative research-chemical estimates and were not verified against live vendor listings in this session.
Papers
- Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, Kozina LS, Advances in Gerontology, 2016 · PMID 28539025
The endothelin-1, connexin and sirtuin-1 results in normal, atherosclerotic and restenotic endothelium. This is the whole vascular case for Vesugen and it is in vitro.
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease Khavinson VK, Lin'kova NS, Umnov RS, et al., Bulletin of Experimental Biology and Medicine, 2021 · PMID 34173097
The same peptide framed as a neurogenesis regulator, which is worth reading precisely because it contradicts the tissue-specificity marketing.
- Short peptides stimulate serotonin expression in cells of brain cortex Khavinson VKh, Lin'kova NS, Tarnovskaya SI, et al., Bulletin of Experimental Biology and Medicine, 2014 · PMID 24909721
Includes KED among the short peptides tested in cortical cells - more evidence that these peptides are not tissue-restricted in the way the naming implies.
- Short Peptides Regulate Gene Expression Khavinson VK, Lin'kova NS, Tarnovskaya SI, Bulletin of Experimental Biology and Medicine, 2016 · PMID 27909961
The general model statement covering KED alongside the rest of the Cytogen set.
- Study of interactions between DNA and tetrapeptides using methods of molecular mechanics Tarnovskaya SI, Yakutseni PP, Khavinson VKh, Bulletin of Experimental Biology and Medicine, 2014 · PMID 24770759
The molecular-mechanics docking work that underpins the major-groove binding model for this family.